GRI Bio increases at-the-market offering capacity to $322,468 after $3.6M already sold

GRI Bio, Inc.

On December 20, 2024, GRI Bio filed a prospectus supplement to increase shares issuable under its ATM agreement with H.C. Wainwright to up to $322,468.
The company had previously sold approximately $3,604,683 of shares under the same Sales Agreement dated May 20, 2024.
An opinion from Mintz, Levin law firm on the legality of the share issuance was attached as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.